拜耳旗下Askbio的Viralgen将为帕金森病基因疗法二期临床试验提供商业化规模药物

投资观察
Apr 20

拜耳集团宣布,其子公司Askbio的病毒载体生产平台Viralgen,将为治疗帕金森病的在研基因疗法REGENERATE-PD的第二阶段临床试验提供商业化规模的药物产品。该试验旨在评估基因疗法对帕金森病患者的潜在疗效与安全性。

此次合作标志着拜耳在基因治疗领域的重要布局,Viralgen作为基因疗法关键成分——病毒载体的专业生产商,其参与有助于保障临床试验药物的供应质量与规模。REGENERATE-PD项目若进展顺利,有望为帕金森病患者提供新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10